Product Pipeline Compound Platform Indication Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA Partner Pidnarulex CX-5461 G-quadruplex (stabilizer) Breast Cancer Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA CA Dream team/CCTG Pidnarulex CX-5461 G-quadruplex (stabilizer) Ovarian Cancer/Breast/Other Cancer Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA/CA Pidnarulex CX-5461 G-quadruplex (stabilizer) Haematologic Malignancies Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA AU PMCC Pidnarulex CX-5461 G-quadruplex (stabilizer) Prostate Cancer(Combo with PARPi) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA AU PCF/Pfizer/PMCC Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Cholangiocarcinoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA/KR/TW Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Basal cell carcinoma(BCC) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Medulloblastoma(MB) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA PBTC/Stanford Univ. Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) COVID-19 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA Taiwan NCKUH Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Community-Acquired Pneumonia (CAP) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA Taiwan/USA